Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

Status:
Completed

Trial end date:
2015-05-20

Target enrollment:

Participant gender:

The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.

Phase 2

Amgen
Celgene Corporation

Apremilast
Thalidomide